에 대한 최신 뉴스 ARK Genomic Revolution ETF (BATS:ARKG)

ARK Genomic Revolution Multi-Sector ETF

Healthcare

Other

Technology

Financial Services

The Fund is an actively managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80 percent of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics* revolution (Genomics Revolution Companies). Under normal circumstances, substantially all of the Funds assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Funds investments will include micro-, small-, medium- and large-capitalization companies. The Funds investments in foreign equity securities will be in both developed and emerging markets.

Twist Bioscience Corp.

Caredx

Crispr Therapeutics Ag

Recursion Pharmaceuticals, Inc.

Ionis Pharmaceuticals Inc

Intellia Therapeutics

Beam Therapeutics Inc

Schrodinger, Inc.

Adaptive Biotechnologies Corporation

10X Genomics Inc

ARK Genomic Revolution ETF

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

$BTC

ARKW

MRNA

수요일에 캐시 우드의 아크 인베스트가 블록(NYSE:SQ)와 모더나(NASDAQ:MRNA)에 대해 상당한 거래를 했다.

SQ 거래

아크 인베스트는 비트코인(CRYPTO:BTC)에 초점을 맞춘 회사의 최근 긍정적인 2분기 실적에도 불구하고 잭 도시(Jack Dorsey)가 주도하는 블록의 상당량의 주식을 매각했다. 이번 매도는 ARK Innovation ETF(NYSE:ARKK)에서 23,473주의 주식을 매도한 것으로, 수요일 종가 기준 $73.53에 약 172만 달러에 해당한다. 특히, 이는 우드가 블록 주식을 매도하는 2일 연속이다. 화요일에 아크는 17,816주의 주식을 매도하여 128만 달러를 확보했다.

캐시 우드, 잭 도시의 비트코인 중심 기업 블록 주식 매도 – 아크도 모더나, 로빈후드 주식 매각

목요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)가 모더나(NASDAQ:MRNA)의 주식을 대량 매도한 주요 사건이 있었다. 이 결정은 분석가들의 혼재된 정서와 모더나가 최근 발표한 포스트-COVID 로드맵을 배경으로 이루어졌다.

아크 인베스트, 포스트 코로나 계획에도 불구라고 모더나 주식 9백만 달러 이상 매각

ARK GENO REVO UCITS ETF USD ACC ETF

ARK GENOMIC REVOLUTION ETF

Guidance

EXAS

Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.34 by 17.65 percent. The company reported quarterly sales of $718.100 million which missed the analyst consensus estimate of $724.700 million by 0.91 percent. This is a 6.02 percent increase over sales of $677.300 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand Q3 2024 Adj. EPS $0.40 Beats $0.34 Estimate, Sales $718.100M Miss $724.700M Estimate

Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(1.11) by 25.23 percent. This is a 8.79 percent increase over losses of $(0.91) per share from the same period last year.

PCVX

Vaxcyte Q3 EPS $(0.83) Beats $(1.11) Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) raises FY2024 sales outlook from $201.00 million-211.00 million to $204.00 million-211.00 million.

TMCI

Treace Medical Concepts Raises FY2024 Sales Guidance from $201.00M-211.00M to $204.00M-211.00M

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.84 by 16.67 percent. The company reported quarterly sales of $504.600 million which beat the analyst consensus estimate of $502.669 million by 0.38 percent. This is a 5.37 percent increase over sales of $478.900 million the same period last year.

MASI

Masimo Q3 2024 Adj. EPS $0.98 Beats $0.84 Estimate, Sales $504.600M Beat $502.669M Estimate

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. The company reported quarterly sales of $709.00 million which missed the analyst consensus estimate of $717.66 million by 1.21 percent. This is a 12.84 percent increase over sales of $628.34 million the same period last year.

Exact Sciences Q3 2024 GAAP EPS $(0.21) Misses $(0.20) Estimate, Sales $709.00M Miss $717.66M Estimate

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $62.400 million which beat the analyst consensus estimate of $58.025 million by 7.54 percent. This is a 152.63 percent increase over sales of $24.700 million the same period last year.

NCMI

National CineMedia Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $62.400M Beat $58.025M Estimate

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) lowers FY2025 sales outlook from $450.00 million-490.00 million to $430.00 million-470.00 million vs 458.78M analyst estimates.

AVNW

Aviat Networks Lowers FY2025 Sales Guidance from $450.00M-490.00M to $430.00M-470.00M vs 458.78M Est.

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 3.95 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $33.251 million which beat the analyst consensus estimate of $32.517 million by 2.26 percent. This is a 47.76 percent increase over sales of $22.504 million the same period last year.

RYTM

Rhythm Pharmaceuticals Q3 2024 GAAP EPS $(0.73) Beats $(0.82) Estimate, Sales $33.251M Beat $32.517M Estimate

Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. The company reported quarterly sales of $167.900 million which missed the analyst consensus estimate of $171.192 million by 1.92 percent. This is a 4.01 percent decrease over sales of $174.909 million the same period last year.

CRCT

Cricut Q3 2024 Adj. EPS $0.05, Inline, Sales $167.900M Miss $171.192M Estimate

Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) reported quarterly earnings of $1.56 per share which beat the analyst consensus estimate of $1.33 by 17.29 percent. This is a 3.31 percent increase over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $153.87 million which beat the analyst consensus estimate of $150.70 million by 2.10 percent. This is a 8.36 percent increase over sales of $142.00 million the same period last year.

QLYS

Qualys Q3 2024 Adj EPS $1.56 Beats $1.33 Estimate, Sales $153.87M Beat $150.70M Estimate

PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $15.256 million which beat the analyst consensus estimate of $14.822 million by 2.93 percent. This is a 23.03 percent increase over sales of $12.400 million the same period last year.

PAYS

PaySign Q3 2024 GAAP EPS $0.03 Beats $0.01 Estimate, Sales $15.256M Beat $14.822M Estimate

RARE

Ultragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est

Share Repurchase Program:
The Company's board of directors (the "Board") has approved a new share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company is authorized to repurchase up to $100.0 million in shares of the Company's common stock, inclusive of fees and commissions. This program replaces the Company's previous share repurchase program adopted in 2021, under which $9.4 million remained available for repurchase. The 2024 Share Repurchase Program is effective immediately and does not have an expiration date.
Repurchases under the 2024 Share Repurchase Program may be made, from time to time, in amounts and prices the Company deems appropriate and may be made pursuant to a trading plan intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Repurchases by the Company under the 2024 Share Repurchase Program will be subject to general market and economic conditions, applicable legal requirements and other considerations. The 2024 Share Repurchase Program may be suspended, modified or discontinued by the Board at any time without prior notice at the Company's discretion.

Buybacks

Grocery Outlet Holding Corp. Has Approved A New Share Repurchase Program Pursuant To Which The Company Is Authorized To Repurchase Up To $100M In Shares Of The Company's Common Stock,

Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $3.221 billion which Beat the analyst consensus estimate. This is a 11.54 percent decrease over sales of $3.64 billion the same period last year.

LUMN

Lumen Technologies Q3 2024 Adj EPS $(0.13) Misses $(0.09) Estimate, Sales $3.221B Beat $3.218B Estimate

Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.18) by 144.44 percent. The company reported quarterly sales of $854.000 thousand which missed the analyst consensus estimate of $6.477 million by 86.81 percent. This is a 24.85 percent increase over sales of $684.000 thousand the same period last year.

EOSE

Eos Energy Enterprises Q3 2024 Adj. EPS $(0.44) Misses $(0.18) Estimate, Sales $854.000K Miss $6.477M Estimate

Momentum investing is all about the idea of following a stock&#39;s recent trend, which can be in either direction. In the &#39;long&#39; context, investors will essentially be &quot;buying high, but hoping to sell even higher.&quot; And for investors following this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the <a href="https://www.zacks.com/education/stock-style-scores/momentum-trading" target="_blank">Zacks Style Scores</a>, helps address this issue for us.
Below, we take a look at U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. U.S. Bancorp currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
<h3>Set to Beat the Market?</h3>
In order to see if USB is a promising momentum pick, let&#39;s examine some Momentum Style elements to see if this company holds up.
Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For USB, shares are up 0.21% over the past week while the Zacks Banks - Major Regional industry is up 0.33% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 6.12% compares favorably with the industry&#39;s 4.51% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of U.S. Bancorp have risen 13.79%, and are up 33.8% in the last year. On the other hand, the S&amp;P 500 has only moved 7.29% and 32.85%, respectively.
Investors should also pay attention to USB&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. USB is currently averaging 8,694,755 shares for the last 20 days.
<h3>Earnings Outlook</h3>
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with USB.
Over the past two months, 6 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost USB&#39;s consensus estimate, increasing from $3.86 to $3.92 in the past 60 days. Looking at the next fiscal year, 8 estimates have moved upwards while there have been 1 downward revision in the same time period.
<h3>Bottom Line</h3>
Given these factors, it shouldn&#39;t be surprising that USB is a #2 (Buy) stock and boasts a Momentum Score of B. If you&#39;re looking for a fresh pick that&#39;s set to soar in the near-term, make sure to keep U.S. Bancorp on your short list.
<a href="https://www.zacks.com/stock/news/2364640/u-s-bancorp-usb-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2364640">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Trading Ideas

General

U.S. Bancorp Is A Great Momentum Stock: Should You Buy?

Contracts

Eos Energy Announced A New Agreement With City Utilities To Provide 216 MWh Of Energy Storage For Two Project Sites In Missouri: Terms Not Disclosed

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) sees Q4 sales of $82.000 million-86.000 million vs $89.27 million estimate.

National CineMedia Sees Q4 Sales $82.000M-86.000M vs $89.27M Est.

Outlook:
The Company is updating key guidance figures for fiscal 2024 as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Previous</td>
<td>Current</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New store openings, net(2)</td>
<td>62 to 64</td>
<td>66</td>
</tr>
<tr>
<td>Net sales</td>
<td>$4.30 billion to $4.35 billion</td>
<td>slightly above $4.35 billion</td>
</tr>
<tr>
<td>Comparable store sales increase</td>
<td>~3.5%</td>
<td>~2.4%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>~30.5%</td>
<td>~30.4%</td>
</tr>
<tr>
<td>Adjusted EBITDA(1)</td>
<td>$252 million to $260 million</td>
<td>$237 million to $242 million</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share(1)</td>
<td>$0.89 to $0.95</td>
<td>$0.77 to $0.80</td>
</tr>
<tr>
<td>Capital expenditures (net of tenant improvement allowances)</td>
<td>~$200 million</td>
<td>~$200 million</td>
</tr>
</tbody>
</table>
</figure>

Grocery Outlet Holding Corp. Updates FY24 EPS Guidance From $0.89-$0.95 To $0.77-$0.80 Vs $0.88 Est.; Revenue From $4.30B-$4.35B To Slightly Above $4.35B Vs $4.37B Est.

Thematic Investing: More Than Just A Good Story

Project $1M Q3 '24: The Goal Is In Sight

Default Risk Eases For Most U.S. Market Sectors In Q3 2024

Keep Your Eye On The CAR-T

Managed Care Insurers See Wall Street Dip As Earnings Fall Short

With 2024 drawing to a close, investors are likely wondering which Cathie Wood ETF has been the best-performing for the year. Ark Invest has been b...

Comments

ARK Genomic Revolution ETF

뉴스

에 대한 최신 뉴스 ARK Genomic Revolution ETF (BATS:ARKG)

금요일, 11월 01, 2024

목요일, 10월 17, 2024

금요일, 10월 11, 2024

화요일, 8월 06, 2024

목요일, 6월 13, 2024

목요일, 5월 30, 2024

수요일, 5월 29, 2024

월요일, 5월 06, 2024

화요일, 4월 16, 2024

화요일, 4월 09, 2024

뉴스

파트너 / 기고자

벤징가 글로벌